AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
mexiletine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1794 | 31828-71-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.80 | g | O |
| 0.80 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 9.50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 95.63 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 87 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 5.90 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.36 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 9.90 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,IKBKB,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,ZAP70 | 46 | |||
| kinase-selectivity-class | AXL,BRAF,CSF1R,DDR1,EPHB4,ERBB2,GRK2,LYN,MAPK7,PDK4,PRKCD,SIK2,SIK3,STK33 | 14 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 0.472 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| rat-kpuu-brain | Rat brain Kpuu | 0.387 | % | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 30, 1985 | FDA | ||
| Dec. 18, 2018 | EMA | Lupin Europe GmbH |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Body tinea | 258.98 | 37.83 | 45 | 2192 | 2103 | 90624107 |
| Inhibitory drug interaction | 235.22 | 37.83 | 44 | 2193 | 3119 | 90623091 |
| Infection susceptibility increased | 231.88 | 37.83 | 45 | 2192 | 3881 | 90622329 |
| Poor quality sleep | 212.17 | 37.83 | 59 | 2178 | 24634 | 90601576 |
| Glucose tolerance impaired | 200.03 | 37.83 | 45 | 2192 | 7940 | 90618270 |
| Impaired quality of life | 183.75 | 37.83 | 52 | 2185 | 23092 | 90603118 |
| Impaired work ability | 183.64 | 37.83 | 50 | 2187 | 19276 | 90606934 |
| Purpura | 172.50 | 37.83 | 45 | 2192 | 14733 | 90611477 |
| Bone density decreased | 165.35 | 37.83 | 45 | 2192 | 17300 | 90608910 |
| Hyperlipidaemia | 152.95 | 37.83 | 45 | 2192 | 22871 | 90603339 |
| Oral herpes | 136.09 | 37.83 | 45 | 2192 | 33479 | 90592731 |
| Skin disorder | 132.09 | 37.83 | 45 | 2192 | 36661 | 90589549 |
| Cataract | 112.42 | 37.83 | 48 | 2189 | 72044 | 90554166 |
| Cellulitis | 101.52 | 37.83 | 48 | 2189 | 91289 | 90534921 |
| Herpes zoster | 99.90 | 37.83 | 48 | 2189 | 94596 | 90531614 |
| Weight increased | 97.37 | 37.83 | 81 | 2156 | 417846 | 90208364 |
| Immune thrombocytopenia | 96.94 | 37.83 | 28 | 2209 | 13298 | 90612912 |
| Drug ineffective | 84.17 | 37.83 | 133 | 2104 | 1384165 | 89242045 |
| Therapy non-responder | 60.11 | 37.83 | 39 | 2198 | 136665 | 90489545 |
| Contusion | 56.83 | 37.83 | 48 | 2189 | 251168 | 90375042 |
| Ventricular tachycardia | 50.50 | 37.83 | 20 | 2217 | 24688 | 90601522 |
| Insomnia | 47.02 | 37.83 | 49 | 2188 | 333425 | 90292785 |
| Electrocardiogram QT prolonged | 40.22 | 37.83 | 24 | 2213 | 72432 | 90553778 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug ineffective | 125.60 | 22.67 | 162 | 2190 | 630035 | 41988948 |
| Ventricular tachycardia | 95.60 | 22.67 | 42 | 2310 | 30118 | 42588865 |
| Tracheitis | 57.60 | 22.67 | 13 | 2339 | 1026 | 42617957 |
| Muscular dystrophy | 54.32 | 22.67 | 9 | 2343 | 135 | 42618848 |
| Hyperthyroidism | 52.04 | 22.67 | 22 | 2330 | 14319 | 42604664 |
| Hypertonia | 33.57 | 22.67 | 12 | 2340 | 4989 | 42613994 |
| Treatment failure | 32.08 | 22.67 | 27 | 2325 | 62597 | 42556386 |
| Cardiac failure acute | 30.69 | 22.67 | 15 | 2337 | 13618 | 42605365 |
| Cytomegalovirus infection reactivation | 30.37 | 22.67 | 14 | 2338 | 11164 | 42607819 |
| Neurogenic bladder | 29.65 | 22.67 | 9 | 2343 | 2251 | 42616732 |
| Clonus | 25.73 | 22.67 | 9 | 2343 | 3511 | 42615472 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Body tinea | 233.53 | 26.42 | 44 | 4179 | 2071 | 110583005 |
| Infection susceptibility increased | 201.40 | 26.42 | 44 | 4179 | 4354 | 110580722 |
| Drug ineffective | 199.04 | 26.42 | 264 | 3959 | 1520276 | 109064800 |
| Inhibitory drug interaction | 190.80 | 26.42 | 43 | 4180 | 4904 | 110580172 |
| Poor quality sleep | 170.93 | 26.42 | 57 | 4166 | 28020 | 110557056 |
| Glucose tolerance impaired | 166.19 | 26.42 | 44 | 4179 | 9793 | 110575283 |
| Bone density decreased | 144.90 | 26.42 | 44 | 4179 | 15998 | 110569078 |
| Impaired quality of life | 140.21 | 26.42 | 50 | 4173 | 29967 | 110555109 |
| Impaired work ability | 138.67 | 26.42 | 48 | 4175 | 26371 | 110558705 |
| Purpura | 126.79 | 26.42 | 44 | 4179 | 24344 | 110560732 |
| Ventricular tachycardia | 125.36 | 26.42 | 53 | 4170 | 49956 | 110535120 |
| Hyperlipidaemia | 110.27 | 26.42 | 44 | 4179 | 35804 | 110549272 |
| Oral herpes | 110.00 | 26.42 | 44 | 4179 | 36036 | 110549040 |
| Skin disorder | 102.63 | 26.42 | 44 | 4179 | 42869 | 110542207 |
| Cataract | 90.58 | 26.42 | 49 | 4174 | 79436 | 110505640 |
| Herpes zoster | 76.48 | 26.42 | 49 | 4174 | 108330 | 110476746 |
| Immune thrombocytopenia | 70.51 | 26.42 | 28 | 4195 | 22466 | 110562610 |
| Weight increased | 70.07 | 26.42 | 83 | 4140 | 419561 | 110165515 |
| Cellulitis | 69.76 | 26.42 | 49 | 4174 | 125967 | 110459109 |
| Therapy non-responder | 60.07 | 26.42 | 49 | 4174 | 157258 | 110427818 |
| Tracheitis | 55.82 | 26.42 | 13 | 4210 | 1708 | 110583368 |
| Muscular dystrophy | 52.73 | 26.42 | 9 | 4214 | 239 | 110584837 |
| Contusion | 48.86 | 26.42 | 52 | 4171 | 233309 | 110351767 |
| Hyperthyroidism | 44.73 | 26.42 | 22 | 4201 | 29239 | 110555837 |
| Electrocardiogram QT prolonged | 41.69 | 26.42 | 34 | 4189 | 108926 | 110476150 |
| Drug ineffective for unapproved indication | 39.15 | 26.42 | 32 | 4191 | 102806 | 110482270 |
| Insomnia | 32.39 | 26.42 | 53 | 4170 | 360537 | 110224539 |
| Myotonia | 32.04 | 26.42 | 6 | 4217 | 272 | 110584804 |
| Hypertonia | 31.79 | 26.42 | 12 | 4211 | 8394 | 110576682 |
| Cytomegalovirus infection reactivation | 31.69 | 26.42 | 15 | 4208 | 18318 | 110566758 |
| Cardiac failure acute | 27.82 | 26.42 | 15 | 4208 | 24063 | 110561013 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | C01BB02 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY ANTIARRHYTHMICS, CLASS I AND III Antiarrhythmics, class Ib |
| FDA EPC | N0000175426 | Antiarrhythmic |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D026941 | Sodium Channel Blockers |
| MeSH PA | D049990 | Membrane Transport Modulators |
| MeSH PA | D061567 | Voltage-Gated Sodium Channel Blockers |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| CHEBI has role | CHEBI:38070 | anti-arrhythmia drug |
| CHEBI has role | CHEBI:53784 | antispasmodic drug |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Ventricular arrhythmia | indication | 44103008 | |
| Myotonic disorder | indication | 193237003 | DOID:450 |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Complete atrioventricular block | contraindication | 27885002 | |
| Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
| Low blood pressure | contraindication | 45007003 | |
| Chronic heart failure | contraindication | 48447003 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Cardiogenic shock | contraindication | 89138009 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Second degree atrioventricular block | contraindication | 195042002 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Smokes tobacco daily | contraindication | 449868002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.01 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium channel protein type 2 subunit alpha | Ion channel | BLOCKER | IC50 | 5.54 | CHEMBL | CHEMBL | |||
| Sodium channel protein type 4 subunit alpha | Ion channel | BLOCKER | IC50 | 4.38 | WOMBAT-PK | CHEMBL | |||
| Sodium channel protein type 9 subunit alpha | Ion channel | BLOCKER | Ki | 4.89 | CHEMBL | CHEMBL | |||
| Sodium channel protein type 10 subunit alpha | Ion channel | BLOCKER | IC50 | 4.25 | CHEMBL | CHEMBL | |||
| Sodium channel protein type 5 subunit alpha | Ion channel | BLOCKER | IC50 | 4.53 | WOMBAT-PK | CHEMBL | |||
| Sodium channel subunit beta-4 | Ion channel | WOMBAT-PK | |||||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 2B | GPCR | Ki | 6.14 | DRUG MATRIX | |||||
| Sodium channel protein type 1 subunit alpha | Ion channel | IC50 | 4.96 | CHEMBL | |||||
| Potassium channel subfamily K member 3 | Ion channel | IC50 | 4.01 | CHEMBL | |||||
| Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 | Ion channel | IC50 | 3.51 | WOMBAT-PK | |||||
| Solute carrier family 22 member 2 | Transporter | IC50 | 4.26 | WOMBAT-PK | |||||
| Potassium channel subfamily K member 2 | Ion channel | IC50 | 5.39 | CHEMBL | |||||
| Glucosylceramidase | Enzyme | Kd | 4.43 | CHEMBL | |||||
| Sodium channel subunit beta-1 | Ion channel | WOMBAT-PK | |||||||
| Sodium channel subunit beta-2 | Ion channel | WOMBAT-PK | |||||||
| Sodium channel subunit beta-3 | Ion channel | WOMBAT-PK | |||||||
| Sodium channel protein type X alpha subunit | Ion channel | IC50 | 4.51 | CHEMBL | |||||
| Sodium channel protein type 9 subunit alpha | Ion channel | IC50 | 4.96 | CHEMBL | |||||
| Sodium channel protein type 1 subunit alpha | Ion channel | IC50 | 4.68 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019837 | VUID |
| N0000147925 | NUI |
| D00639 | KEGG_DRUG |
| 5370-01-4 | SECONDARY_CAS_RN |
| 4019066 | VANDF |
| 4019837 | VANDF |
| C0025887 | UMLSCUI |
| CHEBI:6916 | CHEBI |
| CHEMBL558 | ChEMBL_ID |
| DB00379 | DRUGBANK_ID |
| CHEMBL1200606 | ChEMBL_ID |
| D008801 | MESH_DESCRIPTOR_UI |
| 4178 | PUBCHEM_CID |
| 3262 | INN_ID |
| 2629 | IUPHAR_LIGAND_ID |
| 1U511HHV4Z | UNII |
| 142138 | RXNORM |
| 1108 | MMSL |
| 5109 | MMSL |
| d00300 | MMSL |
| 000630 | NDDF |
| 004485 | NDDF |
| 108500007 | SNOMEDCT_US |
| 372909002 | SNOMEDCT_US |
| 96298001 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8739 | CAPSULE | 150 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8740 | CAPSULE | 200 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8741 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-730 | CAPSULE | 150 mg | ORAL | ANDA | 22 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-731 | CAPSULE | 200 mg | ORAL | ANDA | 22 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-732 | CAPSULE | 250 mg | ORAL | ANDA | 22 sections |
| Mexiletine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-036 | CAPSULE | 150 mg | ORAL | ANDA | 17 sections |
| Mexiletine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-037 | CAPSULE | 200 mg | ORAL | ANDA | 17 sections |
| Mexiletine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 31722-038 | CAPSULE | 250 mg | ORAL | ANDA | 17 sections |
| Mexiletine Hydrochloride | Human Prescription Drug Label | 1 | 33342-555 | CAPSULE | 150 mg | ORAL | ANDA | 17 sections |
| Mexiletine Hydrochloride | Human Prescription Drug Label | 1 | 33342-556 | CAPSULE | 200 mg | ORAL | ANDA | 17 sections |
| Mexiletine Hydrochloride | Human Prescription Drug Label | 1 | 33342-557 | CAPSULE | 250 mg | ORAL | ANDA | 17 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-624 | CAPSULE | 150 mg | ORAL | ANDA | 19 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-625 | CAPSULE | 200 mg | ORAL | ANDA | 19 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42291-626 | CAPSULE | 250 mg | ORAL | ANDA | 19 sections |
| MEXILETINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-239 | CAPSULE | 150 mg | ORAL | ANDA | 17 sections |
| MEXILETINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-240 | CAPSULE | 200 mg | ORAL | ANDA | 17 sections |
| MEXILETINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-241 | CAPSULE | 250 mg | ORAL | ANDA | 17 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-379 | CAPSULE | 150 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-380 | CAPSULE | 200 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-381 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
| Mexiletine hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-778 | CAPSULE | 150 mg | ORAL | ANDA | 21 sections |
| MEXILETINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62135-785 | CAPSULE | 250 mg | ORAL | ANDA | 12 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-820 | CAPSULE | 150 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-820 | CAPSULE | 150 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-821 | CAPSULE | 200 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-821 | CAPSULE | 200 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-822 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
| Mexiletine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 62559-822 | CAPSULE | 250 mg | ORAL | ANDA | 20 sections |
| MEXILETINE HYDROCHLORIDE | Human Prescription Drug Label | 1 | 62756-955 | CAPSULE | 150 mg | ORAL | ANDA | 11 sections |